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SUMMARY
Leishmaniasis is a vector-borne neglected tropical disease caused by protozoan parasites of the genus Leishmania for which
there is a paucity of eﬀective viable non-toxic drugs. There are 1·3 million new cases each year causing considerable socio-
economic hardship, best measured in 2·4 million disability adjusted life years, with greatest impact on the poorest com-
munities, which means that desperately needed new antileishmanial treatments have to be both aﬀordable and accessible.
Established medicines with cheaper and faster development times may hold the cure for this neglected tropical disease.
This concept of using old drugs for new diseases may not be novel but, with the ambitious target of controlling or eradi-
cating tropical diseases by 2020, this strategy is still an important one. In this review, we will explore the current state-of-
the-art of drug repurposing strategies in the search for new treatments for leishmaniasis.
Key words: leishmaniasis, repurposing, repositioning, drug discovery.
INTRODUCTION: DRUG REPOSITIONING
The introduction of a new drug from initial concept
topublic release isaslowexpensiveprocess.Developing
a new chemical entity (NCE) drug and delivering it to
market, de novo drug discovery (Fig. 1), is estimated
to take 10–17 years and cost ∼$1·8 billion (Paul
et al. 2010). Moreover, the probability of success is
lower than 10% and the costs of late stage failures
in this process are signiﬁcant and are accounted for
in the high cost of patented drugs. Consequently,
the discovery of new drugs for leishmaniasis, and
other neglected tropical diseases, for which the
average patient suﬀering from visceral leishmaniasis
(VL) exists on an income of less than $2 per day
(WHO, 2002), is simply not a commercially viable
operation for pharmaceutical companies without
signiﬁcant cross-subsidy.
Alternative strategies are therefore needed and the
process of drug repositioning or repurposing, where
new applications for existing drugs or drug candi-
dates are discovered and reﬁned, has become increas-
ingly common (Ashburn and Thor, 2004; Aubé,
2012; Oprea and Mestres, 2012; Andrews et al.
2014; Klug et al. 2016; Jain and Sharma, 2017).
When using a drug repositioning strategy several
development phases necessary to develop NCE
drugs can be bypassed or considerably shortened
(Fig. 1) because candidates will have passed
various checkpoints and information is available
about their pharmacokinetic and safety proﬁles.
Reﬂecting this, the process of ﬁnding new uses for
drugs outside their original indication is becoming
increasingly successful as more companies are
screening their libraries for repositioning candidates.
Figure 2 illustrates two examples of approved drugs
possessing optimum properties for their new indica-
tion. However, it should be noted that these cases are
relatively rare and some development work is still
commonly required. Moreover, whilst serendipity
(phenotypic screening) can play a sizeable role in
identifying repurposed drugs, it is important to
establish the molecular connection between old
drugs and new targets as this information aids the
development of the new therapeutics. Despite
these caveats drug repositioning can reduce time,
cost and risk, and is a particularly attractive
approach for neglected tropical diseases where new
medications are needed urgently to treat the
poorest of people. In this review, we will focus on
the neglected tropical disease, leishmaniasis, and
how repositioning strategies have shown potential
to enable the discovery of new medicines for this
disease.
LEISHMANIASIS
Leishmaniasis is an important vector borne
´Neglected Tropical Disease’ caused by protozoan
parasites of the genus Leishmania (Roberts, 2006).
With over 350 million people world wide considered
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at risk, 12 million people currently infected
(Kedzierski, 2010), one million new cases reported
annually, more than 30 000 deaths each year
(WHO, 2016) and an economic cost that can be
best estimated in terms of 2·4 million disability
adjusted life years, the health challenge is only sur-
passed amongst parasitic diseases by malaria, schis-
tosomiasis and lymphatic ﬁlariasis (Davies et al.
2003; Bern et al. 2008). Consequently, leishmaniasis
has been classiﬁed by the World Health Organization
as Category I: emerging or uncontrolled diseases. In
particular, the spread and severity of infection is exa-
cerbated by its status as an important co-infection of
AIDS patients and the overlap in prevalence of
HIV and Leishmania spp. (Alvar et al. 2008). The
disease is endemic in 98 countries across ﬁve conti-
nents and has strong links with poverty, principally
aﬀecting low income regions of Africa, Asia and
Latin America (Alvar et al. 2012). However, the
impact of the disease is spreading and, reﬂecting
population movements and climate change, leish-
maniasis has also been recorded with growing fre-
quency in Southern Europe (Gradoni, 2013).
Leishmaniasis is transmitted through the bite
of infected female phlebotomine sandﬂies.
Subsequently, in the mammalian host, ﬂagellated
promastigote Leishmania spp. are taken up by
macrophages where they transform into the non-
ﬂagellated amastigote form, proliferate and cause
disease. Infected macrophages can then be taken
up by the insect vector during a second blood
meal, the parasite then transforms back to the pro-
mastigote form and the cycle is perpetuated.
Importantly, many Leishmania spp. can infect mul-
tiple mammalian species leading to animal reservoirs
for human infection, most notably in canines
(Solano-Gallego et al. 2011).
Human disease is caused by 20 of the 31 parasite
species that infect mammals with the diﬀerent
species leading to diﬀerent clinical manifestations
(Akhoundi et al. 2016). Depending on parasite
tropism for skin or visceral macrophages, and host
immune status, clinical forms range from localized
cutaneous leishmaniasis (CL), diﬀuse CL, dissemi-
nated CL, mucosal CL, to visceral leishmaniasis
(VL). The most common form of the disease is CL
which, although not fatal, leads to slow growing
skin lesions, which leave permanent scars and in
some cases cause serious disability. Mucocutaneous
leishmaniasis is the most disﬁguring form and
causes destruction of soft tissue in the nose, mouth
Fig. 1. Drug discovery and repositioning pathways (adapted from Guha et al. 2015).
Fig. 2. Examples of old drugs directly repositioned as
treatments for new diseases and dysfunctions.
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and throat. In contrast, VL is the most severe form
of the disease as it aﬀects the vital organs of the
body and is fatal if left untreated (CDC, 2016).
Treatment of leishmaniasis is challenging and
there are currently no vaccines or prophylactic
drugs to prevent human infection. For over 70
years, the mainstay of antileishmanial therapy has
been pentavalent antimonials (Pentostam 3 and
Glucantime 4) which are administered by slow intra-
venous or intramuscular injections (Kedzierski et al.
2009). The mode of action is not fully understood
but one possibility involves the biological reduction
of Sb(V) to Sb(III) by the parasite or by infected
host cells to create antileishmanial activity (Shaked-
Mishan et al. 2001; Krauth-Siegel & Comini 2008).
Unfortunately, antimonials are also toxic (Sundar
and Chakravarty, 2010b) and reports of resistance
are becoming increasingly common. For example,
a study of the eﬃcacy of Pentostam 1, in North
Bihar, India, revealed that only 36% of patients
could be cured when treated with a dose of 20 mg
kg−1 for 30 days (Croft et al. 2006).
For the past seven decades, amphotericin B 5
(AmpB) and pentamidine 6 have been used in cases
of antimonial failure (Kedzierski et al. 2009).
Pentamidine 6 is an antimicrobial medication that
was commonly used as a second line, parenteral,
treatment for leishmaniasis in the case of antimonial
failure. The primary mode of action of pentamidine
6 in kinetoplastids is not well understood but there is
some evidence that it inhibits the active transport
system and disrupts the mitochondrial membrane
potential. However, pentamidine 6 has lower
eﬃcacy than amphotericin B 5 (Lockwood and
Moore, 2010) and this, coupled with severe toxicity,
have resulted in a gradual decline in its use (No,
2016).
The antifungal drug AmpB 5, ﬁrst isolated in
1955, was reported to have antileishmanial activity
in the early 1960s. AmpB 5 binds to ergosterol,
forming pores in the membrane, which leads to the
death of the parasite (Kamin ́ski, 2014). Whilst
severe side eﬀects limited its use, liposomal formula-
tions that circumvent these problems have been
developed. However, a course of L-AmpB 5 still
requires parenteral administration and, without
extensive subsidy is expensive (up to $3000 per
course). This makes L-AmpB inaccessible to most
patients who live in the poorest, least developed
regions. In comparison, an equivalent course of
pentavalent antimonials costs between $150 and
$198 (de Menezes et al. 2015). Despite this, L-
AmpB 5 is now often preferred over Penstostam 3
for VL because it is less toxic and there are fewer
reports of parasitic resistance (Croft et al. 2006;
Sundar and Singh, 2016).
Along with L-AmpB, paromomycin 7 and milte-
fosine 8 are now approved drugs for VL (Sundar
and Chakravarty, 2015). Paromomycin 7 is an
antibiotic and a relatively new therapy for the paren-
teral treatment of VL in India. It has been shown to
be eﬀective and relatively cheap ﬁrst-line treatment
with low toxicity, requiring a course of 15 mg kg−1
for 21 days (Musa et al. 2010; No, 2016). The mech-
anism of action is not fully understood but it is
thought to inhibit protein synthesis (Fernández
et al. 2011). As with the other treatments there are
drawbacks, the drug is administered by injection
(Sundar et al. 2007) and shows poor eﬃcacy in
some regions in Africa (Hailu et al. 2010).
As discussed above, these current medications all
involve prolonged parenteral administration, which
leads to many complications, including poor patient
compliance, blood-borne disease fromunsanitary con-
ditions and the need for medical facilities. Therefore,
in the past two decades there has been a focus on devel-
oping neworal therapies. In 2002miltefosine 8, origin-
allydevelopedas ananticancer agent,was introducedas
the ﬁrst oral antileishmanial agent (Soto and Berman,
2006). The primary mechanism of action is poorly
understood, although the drug is thought to involve
disruption of ether-phospholipid metabolism, gly-
cosylphosphatidylinositol anchor biosynthesis and
signal transduction within the parasite (No, 2016).
Miltefosine 8 eﬃcacy against both VL and CL has
been reported and, in 2014, the US Food and
Drug Administration approved the drug for all
forms of leishmaniasis (Dorlo et al. 2012).
However, this oral therapy does have limitations,
including high costs and teratogenic eﬀects.
Moreover, the long-term eﬀectiveness of miltefosine
8 is questionable, with reports of VL relapses in
Nepalese patients treated with this drug. In add-
ition, miltefosine 8 resistance is readily induced in
Leishmania donovani in vitro (Seifert et al. 2003).
In conclusion, all current treatments (Fig. 3) have
serious limitations such as high cost, route of
administration, severe toxic side eﬀects and increas-
ing drug resistance. Currently, there are some new
therapies under clinical investigation as monother-
apies or in combination with existing antileishma-
nials (Bahamdan et al. 1997; Alrajhi et al. 2002;
Momeni et al. 2002; Machado et al. 2007; Sundar
et al. 2011; ClinicalTrials.gov, 2016). These include
paromomycin 7 topical cream, currently in phase 3
trials as a treatment for CL, and sitamaquine 9 in
phase 2 to treat VL.
REPOSITIONING OF DRUGS TARGETING
LEISHMANIASIS
Signiﬁcantly, as noted above in the Introduction,
many of the existing therapies for leishmaniasis are
licensed or were initially intended for other illnesses.
For example, Amphotericin B 5 is an antifungal
drug, paromomycin 7 is an aminoglycoside anti-
biotic used to treat intestinal infections, and miltefo-
sine 8 was originally developed as an anticancer
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agent. This section will review drugs for diﬀerent
disease states; cancer, microbial infection, depres-
sion, allergies and others; that have shown potential
to be repurposed as new antileishmanial therapies,
and discuss their putative parasitic drug targets.
It should be noted that many natural products
often used in traditional medicines have antileishma-
nial activity, including vast numbers of diﬀerent
alkaloids (Mishra et al. 2009a, b), ﬂavonoids
(Mittra et al. 2000; da Silva et al. 2012) chalcones
(Chen et al. 1994; Boeck et al. 2006; Aponte et al.
2010; de Mello et al. 2014) and terpenoids (Rosa
et al. 2003; Torres-Santos et al. 2004; Arruda et al.
2005; Mazoir et al. 2011). These compounds have
been discussed extensively in previous literature
(Mishra et al. 2009a, b; Schmidt et al. 2012; Singh
et al. 2014a) however, they are structurally
complex molecules, often aﬀecting multiple targets
and possess properties that make them unlikely to
be orally active drugs. As such the greatest potential
of natural products is for the identiﬁcation of novel
targets required to underpin target-based drug dis-
covery and not as starting points for a repositioning
strategy and therefore they will not be discussed
further in this review.
Anticancer drugs
Both cancerous cells and Leishmania spp. have the
ability to proliferate in a host organism for prolonged
periods of time and someenzymes targetedby antican-
cer therapies can also be used in the development of
antileishmanials (Fig. 4, Table 1) (Klinkert and
Heussler, 2006; Uliana and Barcinski, 2009).
Kinases have long been recognized as a major
target in oncology and this has spawned a number
Fig. 3. Current antileishmanials.
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of eﬀorts to repurpose a range of kinase inhibitors for
leishmaniasis. For example, miltefosine 8 is the ﬁrst,
and still the only, oral drug in the treatment of VL
but was originally developed as a treatment for
breast cancer. Like many anticancer drugs, miltefo-
sine 8 induces apoptosis through kinase inhibition.
In this case the PI3K/Akt/PkB pathway is targeted
and it has been reported that inhibition of this
pathway may inﬂuence the susceptibility of host
cell to Leishmania infection (Dorlo et al. 2012).
The genomes of trypanosomatids encode at least
12 proteins belonging to the PI3K protein super-
family, many of which are unique to the parasites.
The Target of Rapamycin (TOR) kinase is a
member of the PI3K-related kinase (PKK) subfamily
and has a central role in fundamental processes such as
growth, cell shape and autophagy. Trypanosomatids
possess four distinct genes belonging to the TOR
family whereas mammals only possess one mTOR
protein. On this basis, a targeted set of eight known
mTOR inhibitors with varied potencies and selectiv-
ity for mTOR/PI3K were screened against
Trypanosoma brucei, Trypanosoma cruzi, cutaneous
Leishmania major and visceral L. donovani. From
these data, the mTor/PI3K inhibitor, Dactolisib
10, was identiﬁed as being the most active against
all the species tested and therefore was tested in
animal models of T. brucei rhodesiense, T. cruzi and
Fig. 4. Treatments for cancer that could be repurposed as antileishmanials.
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L. major. Unfortunately, no eﬃcacy was observed
against either T. cruzi or L. major; this may reﬂect
the need for the drug to cross into the phagolysoso-
mal compartment where the parasite resides. In
contrast, and consistent with this hypothesis,
Dactolisib signiﬁcantly reduced the parasite burden
and extended the survival of mice infected with T.
brucei rhodesiense (Diaz-Gonzalez et al. 2011), a
blood stream parasite. Although the exact mechan-
ism of action has yet to be identiﬁed this investiga-
tion has demonstrated a potential target in the
search for antitrypanosomal therapies.
Similar small scale focused screens against speciﬁc
kinase targets have been conducted. For example,
through exploring Aurora kinases, hesperidin 11
has been identiﬁed as a putative antileishmanial
lead but host cell toxicity was observed when the
compound was screened against the hepatic cancer
cell line (Patel et al. 2014). Although, further struc-
ture-activity relationship (SAR) studies demon-
strated that these inhibitors are not general toxins
but can be modiﬁed to improve selectivity, useful
antileishmanial selectivity was not obtained. More
signiﬁcantly, and consistent with other reports (De
Muylder et al. 2011), there was no correlation
between activity against promastigote and axenic
amastigote with in this case the latter being the less
sensitive form.
Whilst target-based screening is an attractive strat-
egy, the need for a speciﬁc orthologous target protein
may not be essential as many kinase inhibitors aﬀect
multiple proteins and simply the proven cellular
accessibility of these compounds is a suﬃcient start-
ing point. For example, whilst tyrosine kinases are
not expressed in trypanosomatids, protein phosphor-
ylation occurs in parasites and therefore kinase inhi-
bitors may interact with other enzymes (Karaman
et al. 2008; Peña et al. 2015). Reﬂecting this, in a
screen of eleven tyrosine kinase inhibitors, sunitib
12, sorafenib 13 and lapatinib 14 showed antileish-
manial activity against intracellular L. donovani
amastigotes (Sanderson et al. 2014). Control experi-
ments conﬁrmed that the leishmanial targets were
unlikely to be the same as those found in mammalian
cells and these kinase inhibitors showed a degree of
selectivity against amastigotes compared with mam-
malian cells. In addition, an oral dose of sunitib 12,
sorafenib 13 and lapatinib 14 reduced liver parasite
burden in mice infected with L. donovani. Whilst
these screens identify new leads, the challenge for
such studies is in the identiﬁcation of the actual
target to guide further optimization.
Kinases also proved to be the most common pre-
dicted target from a set of 192 antileishmanial com-
pounds identiﬁed from a high throughput phenotypic
screen of 1·8 million compounds against representative
kinetoplastid species, includingL. donovani (Peña et al.
2015). However, since most of these compounds have
no literature precedent this was not strictly a
repurposing study, and further discussion is outside
the scope of this review. Finally, an interesting, and
somewhat diﬀerent, study involving the repurposing
of kinase inhibitors, was the use of imatinib 15
(Gleevec, another tyrosine kinase inhibitor used in
the treatment of multiple cancers) to target the host
macrophage AbI and Arg kinases believed to be
involved in parasite entry to the cell. Mice infected
with L. amazonenesis were treated with oral imatinib,
which resulted in smaller lesions that developed later
and a reduction in parasite burden relative to controls.
(Wetzel et al. 2012). Imatinib is a clinically approved
drugwith relatively benign side eﬀects when compared
with antileishmanials on the market. It would be of
great beneﬁt to further understand the cell entry
pathway to provide new lines of therapy for
leishmaniasis.
The approach of starting with inhibitors with
known modes of action, for example against mam-
malian kinases, and screening for new antileishma-
nial activities for which orthologous protozoal
targets can then be identiﬁed is an attractive
concept. However, good levels of host parasite
selectivity are required before any hits can be repur-
posed as antiparasitic therapeutics. This was nicely
illustrated in a study exploring Lysine Deacetylases
(KDAC) as putative antileishmanial drug targets.
KDACs are one of the most studied epigenetic
drug targets of humans (Wang et al. 2015) and inhib-
ition of their activity is a validated strategy for cancer
treatment (Patil et al. 2010). As with the kinases dis-
cussed above, Leishmania spp. have multiple genes
encoding diﬀerent HDACs isoenzymes some of
which are essential to parasite survival (Patil et al.
2010). Whilst, the homology between kinetoplastid
and mammalian KDACs is low (∼40%) much
higher levels of similarity are found in active site
residues (Wang et al. 2015). Reﬂecting this only
one compound, Hydroxamate 16, showed signiﬁcant
selectivity (∼10-fold) between host cell and parasite
and high (nanomolar) activity against axenic
L. donovani amastigotes (Wang et al. 2015).
A ﬁnal class of anticancer agents that have been
shown to have potential as antileishmanials are the
selective estrogen-receptor modulators, tamoxifen
17 and raloxifene 18, used to prevent and treat
breast cancer. Both have been identiﬁed as potential
candidates for leishmaniasis treatment with micro-
molar potency against intracellular Leishmania ama-
zonensis amastigotes (Reimao et al. 2014; Doroodgar
et al. 2016; Trinconi et al. 2016). The mechanism of
action of tamoxifen 17 and raloxifene 18 is still
unclear as estrogen responses have not been
described in Leishmania spp. (Miguel et al. 2007,
2008). However, it has been postulated that tamoxi-
fen 17 causes changes in parasite-membrane proper-
ties and disrupts sphingolipid synthesis (Trinconi
et al. 2016), whereas raloxifene 18 is thought to
damage the cell membrane and the mitochondrion
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of the parasite (Reimao et al. 2014). Whilst the antil-
eishmanial activity of these compounds has not
necessarily been optimized, the proven safety
proﬁle of these repurposed drugs allows them to be
considered as synergists in combination therapies to
help combat growing concerns about the emergence
of parasitic resistance. For instance, combination of
tamoxifen 17 and miltefosine 8 in vitro and in vivo
revealed no interaction between the two drugs and
suggested that tamoxifen could slow the emergence
of miltefosine 8 resistance (Trinconi et al. 2016).
Antimicrobial drugs
An antimicrobial is any compound that kills or
inhibits the growth of a microorganism; this can
include bacteria, fungi, viruses and protozoa.
Antimicrobial drugs that were originally licensed
for other indications have already been repurposed
as antileishmanial therapies. For example, ampho-
tericin B 5 and pentamidine 6 are antifungal medi-
cations and paromomycin 7 is used to treat the
parasitic diseases, cryptosporidiosis and amoebia-
sis. These examples of successfully repurposed
antimicrobials as treatments for leishmaniasis have
encouraged further investigation into the leishma-
nicidal activity of other antimicrobial drugs (Figs
5–8, Table 1).
Antifungals
As discussed above, the main use of amphotericin
B 5 is in the treatment of a wide range of fungal
infections but is now also used to treat VL.
Liposomal amphotericin B 5 is the treatment of
choice for immunocompetent patients in the
Mediterranean region and the preferred drug for
HIV/VL co-infection (Sundar and Chakravarty,
2010a). AmpB functions by binding to ergosterol
disrupting the plasma membrane. This is the
major sterol of the fungal plasma membranes and
there are other antifungal azoles, which inhibit
C14α-demethylase, an essential enzyme in the
biosynthesis of ergosterol,. As the sterol biosyn-
thesis pathway is conserved in Leishmania spp.
parasites and is important for their survival (de
Souza and Rodrigues, 2009), these antifungal
azoles have the potential to be repurposed as antil-
eishmanials. Fluconazole 19 and terbinaﬁne 20,
two antifungal azoles, which have similar modes
of actions, can be administered orally and possess
low levels of toxicity; therefore, the use of these
drugs as putative antileishmanials in clinical trials
can be approached with some conﬁdence. Oral
ﬂuconazole 19 was shown to be a safe and useful
drug for the treatment of CL caused by L. major
(Alrajhi et al. 2002) and was reported to be more
Fig. 5. Antifungal drugs that could be repurposed as antileishmanials.
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eﬃcacious in higher doses after a phase 2 clinical
study (Emad et al. 2011). However, a recent phase
3 clinical trial of the use of high dose ﬂuconazole
19 in the treatment CL caused by L. braziliensis
and L. guyanensis was terminated due to a low
cure rate, suggesting species dependent activity
(ClinicalTrials.gov, 2015a). The potential for
terbinaﬁne 20 as a new treatment for CL was ﬁrst
described in 1997. Signiﬁcantly, at the dosage used,
no patients reported any side eﬀects. However, the
eﬃcacy appears lower than other azole antifungals
notably, ketoconazole 21 and itraconazole 22, and
further investigation is required to optimize the
eﬃcacy of the drug before it can be considered as
an eﬀective solution (Bahamdan et al. 1997). One
method being investigated is using terbinaﬁne 20
in combination therapies. For example, oral terbi-
naﬁne 20 and cryotherapy has completed phase 1
of clinical trials for treatment of CL and results
show a similar level of eﬃcacy to glucantime 2
(Farajzadeh et al. 2015).
Fig. 6. Antiparasitic drugs that could be repurposed as antileishmanials.
Fig. 7. Antibacterial drugs that could be repurposed as
antileishmanials.
Fig. 8. Antiviral drugs that could be repurposed as
antileishmanials.
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Positive results, coupled with attractive pharma-
cokinetic and safety proﬁles, with these antifungal
azoles have encouraged the investigation of similar
compounds. For example, itraconazole 22 and posa-
conazole 23 exhibit in vitro and in vivo activity
against L. amazonensis, L. donovani and L. infantum.
In addition, in a separate study, econazole 24 showed
activity against L. infantum chagasi promastigotes
and similar intramacrophage eﬀectiveness to milte-
fosine 8 (Mesquita et al. 2014).
Antiparasitics
A second source of antimicrobial compounds that
have been exploited as antileishmanials are, not
surprisingly, other antiparasitics. In one approach,
a collection of 400 compounds obtained from
Medicines for Malaria Venture (MMV) were
screened for antileishmanial activity. Signiﬁcantly,
in contrast to many other such approaches, which
use promastigote or axenic amastigotes, this study
developed an assay using intracellular amastigotes,
thus enabling screening against the most clinically
relevant form of the parasite (Freitas-Junior et al.
2012). The results identiﬁed 14 antimalarial drugs
that have antileishmanial activity. The compound of
most interest was the anticancer drug, MMV666080
25, which, with an IC50 of 15 nM, is more potent and
also less toxic than amphotericin B 5. In addition, a
series of substituted aminobenzimidazoles (26–28)
were identiﬁed from this screen as active antileish-
manials with IC50 values ranging from 61 to 134
nM. A current focus for these compounds is to valid-
ate the results using in vivomodels (Khraiwesh et al.
2016).
A second set of studies has focused on the use of
nitazoxanide 29, an oral drug used in the treatment
of infectious diarrhoea caused by the protozoan para-
sites, Cryptosporidium parvum and Giardia lamblia.
The lethal action of nitazoxanide 29 against L. infan-
tum involves upregulation of reactive oxygen species
resulting in oxidative stress and parasite death
(Mesquita et al. 2013). Nitazoxanide 29 also displays
activity against L. donovani and L. amazonensis
(Zhang et al. 2010; Nava-Zuazo et al. 2014), with
spleen and liver parasite load being reduced by
86% in L. donovani infected mice (Zhang et al.
2010). In addition, nitazoxanide 29 demonstrates
low cytotoxicity against mammalian VERO cell
line and exhibits activity against Giardia intestinalis
and Trichomonas vaginalis; therefore derivatives of
nitazoxanide 29 would generally be attractive start-
ing points for new antiparasitic drugs (Nava-Zuazo
et al. 2014).
Due to the closer taxonomy lineage, it would be
expected that anti-trypanosomal drugs would be
more likely repurposed to leishmaniasis than other
antiparasitics. However, apart from pentamidine
used to treat African trypanosomiasis caused by
Trypanosoma gambiense, no other anti-trypanosomal
drugs including those used to treat Chagas Disease
are presently used against leishmaniasis.
Whilst nitroaromatics, such as nitazoxanide 29,
are generally avoided in the pharmaceutical industry
due to the known potential mutagenicity and car-
cinogenicity of the nitro group, recent research has
revealed the potential of nitroaromatics to treat
neglected parasitic diseases (Patterson and Wyllie,
2014). Reﬂecting this, another antiparasitic nitro-
aromatic compound, fexinidazole 30, is being
explored as a potential treatment for leishmaniasis.
Fexinidazole 30 is in clinical trials for treating
African trypanosomiasis (T. brucei) and Chagas
disease (T. cruzi) where the mechanism of action is
proposed to involve reductive activation of the
nitro group by NADH-dependent bacterial-like
nitroreductase. A study involving the overexpres-
sion of the leishmanial orthologue of the nitroreduc-
tase demonstrated that a similar mechanism occurs
in Leishmania spp. Building on this fexinidazole 30
and its two predominant in vivo metabolites (fexini-
dazole sulfoxide and sulfone) displayed excellent
activity against L. donovani promastigotes and
axenic amastigotes. However, fexinidazole was
inactive against intracellular amastigotes whereas
fexinidazole sulfoxide and sulfone remained potent
against intracellular amastigotes (both EC50 values
equal to 5·3 µM). When progressed into a murine
model infected with L. donovani a 98·4% suppression
of infection was observed with a single daily dose of
fexindazole 30 for 5 days (Wyllie et al. 2012). With
this positive data, fexinidazole 30 was progressed
into clinical trials as a treatment for VL. In 2013, a
phase II study tested fexinidazole 30 on 14 patients
suﬀering with VL and all patients showed clinical
improvement during treatment. Unfortunately,
treatment relapses were observed and thus the study
was terminated in 2014 due to lack of eﬃcacy
(ClinicalTrials.gov, 2015b). However, fexinidazole 30
is now being investigated as a combination therapy
with miltefosine 8 in Eastern Africa (DNDi, 2016).
Levamisole 31 is a heterocyclic compound that is
immunoregulatory and an eﬀective antihelminthic
agent (Goldstein, 1978). Since the 1970s it has
been studied as a therapy for CL (Butler, 1978)
and a more recent study compared the eﬀects of lev-
amisole 31 and imidocarb 32, veterinary medicine
used to treat parasite infection, in murine models
infected with L. amazonensis. The results from a
number of parameters (IgG levels, vacuolar area,
megakaryocyte count in spleen and parasite burden)
demonstrate that imidocarb 32 has the most potential
as a therapy for CL (Rodrigues et al. 2006).
Antibacterials
The activity and safety proﬁle of fexinidazole 30
sparked the search for other nitroimidazoles, which
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may have potential as oral treatments for VL. This
identiﬁed the antituberculosis drugs PA-824
(33–34) and delamanid 35, which can also undergo
bioactivation by a nitroreductase, as potential leads
(Patterson et al. 2013; Gupta et al. 2015; Patterson
et al. 2016; Thompson et al. 2016). As with fexinida-
zole 30 the presence of the nitro group has been
shown to be essential for antileishmanial activity
(Patterson et al. 2013, 2016). However the nitrore-
ductase found in Mycobacterium tuberculosis [dea-
zaﬂavin (F420)-dependent nitroreductase (Ddn)]
(Manjunatha et al. 2009), is absent in Leishmania
and over-expression of the leishmanial nitroreduc-
tase did not provide enhanced sensitivity to the
drugs, suggesting a diﬀerent mode of action. This
suggests the potential for future combination ther-
apies involving fexinidazole 30 and these antituber-
culosis drugs. These diﬀerences are reinforced by
the observation that whilst the (S)-enantiomer of
PA-824 33 is currently in phase II clinical trials for
tuberculosis it is the (R)-enantiomer of PA-824
34, which shows superior activity against L. dono-
vani parasites, both in vitro and in vivo, with a
twice daily dose of (R)-PA-824 34 at 100 mg kg−1
eﬀectively curing a murine model of infection, sup-
pressing infection by 99·9% (Patterson et al. 2013).
More recently, the structurally similar compound
delamanid 35 (R-enantiomer) has been demon-
strated to display high activity in vitro against intra-
cellular L. donovani amastigotes. In addition, a
twice-daily oral dose of this nitroimidazole at 30
mg kg−1 for 5 days cured the mice infected with L.
donovani (Patterson et al. 2016). Whilst these com-
pounds appear to show considerable potential, a cau-
tionary note arises from the history of the chimeric
nitroimidazole, DNDI-VL-2098 36. This com-
pound, following promising early results, was at
the ﬁnal stages of preclinical development for the
treatment of VL. However, results from animal
models showed a link between dose, length of treat-
ment and testicular toxicity leading to a decision to
halt progression (DNDi, 2015). Whether this is a
compound speciﬁc eﬀect or a class problem
remains to be established.
Antivirals
Tucaresol 36 is an investigational drug that has
completed phase 2 clinical trials as a treatment for
HIV (Gori et al. 2004; ClinicalTrials.gov, 2008)
and, like the antiparasitic drug Levamisole 31, is an
immunomodulator that demonstrates antileishmanial
activity in vivo. This novel immunomodulator was
inactive in L. donovani intracellular amastigote
assays but showed a reduction in parasite burden
in mice infected with L. donovani. Tucaresol 36
could be delivered orally at an optimum dose of 5
mg kg−1 to produce a 44 to 62% suppression of
liver amastigotes (Smith et al. 2000).
Another drug with immunomodulatory eﬀects
being studied as a therapy for leishmaniasis is imi-
quimod 37. This immune-response modiﬁer is a
treatment for gentil warts caused by human papillo-
maviruses and works through activation of immune
cells, including macrophages. Macrophages are the
host cells of Leishmania and therefore in 1999 a
study was conducted to determine if imiquimod 37
could be used as potential therapy for leishmania.
In vitro results determined that imiquimod 37
could induce leishmanicidal properties in infected
macrophages and a possible mode of action is
through stimulated signal transduction increasing
the synthesis of nitric oxide, which are toxic to the
intracellular parasites. After the positive in vitro
results it was important to test the capabilities of imi-
quimod 37 in vivo. L. major infected mice were
treated with 5% imiquimod 37 cream and a signiﬁ-
cant reduction in the severity of the lesions was
observed (Buates and Matlashewski, 1999) but the
progression of this treatment to human trials
demonstrated that topical application of imiquimod
37 alone was ineﬀective at treating CL (Seeberger
et al. 2003). In 2005, a study focused on new
approaches such as combination therapies and con-
ducted a clinical trial of parental antimonial plus
topical imiquimod 37 to treat patients with CL.
Results from this study showed that 72% of patients
treated with the combination containing 37 achieved
a cure at 3 months vs 35% treated with the vehicle
cream. In addition, accelerated healing and less
prominent scarring was observed in the group
treated with antimonial and imiquimod 37 com-
pared with therapy with antimonial alone demon-
strating that the next clinically available treatment
for leishmaniasis might not rely on one but a com-
bination of drugs (Miranda-Verástegui et al. 2005).
Antihistamines
Antiallergic compounds, such as quercetin found in
Kalanchoe plant extracts, display potent antileish-
manial eﬀects. This reﬂects a capacity to restore
the Th1/Th2T cell balance and also to inhibit mast
cell histamine release (Cruz et al. 2008, 2012;
Muzitano et al. 2008; Gomes et al. 2009; Mlcek
et al. 2016). Consistent with these observations, a
set of seven H1-antagonists were reported to
display activity against L. infantum promastigotes
with IC50 values in the range 13–84 µM (Pinto et al.
2014). The activity recorded for cinnarizine 38
(Fig. 9, Table 1) was particularly noteworthy as,
unlike the other compounds tested, it also demon-
strated potency against intracellular amastigotes
(EC50 = 21 µM and NCTC cells EC50 = 87 µM).
Whilst, initial in vivo experiments using hamsters
infected with L. infantum revealed a lack of
eﬃcacy, a liposomal formulation circumvented this
problem and enabled eﬀective treatment of infection
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in the liver but not the spleen, which could be ascribed
to the higher parasite burden (amastigotes/gram of
organ) in this latter organ. Cinnarizine 38 has also
been described as a calcium channel blocker, which
is signiﬁcant because Reimão et al. (2010) de-
monstrated the activity of eight calcium channel
blockers against intracellular L. infantum amastigotes
(EC50 = 5–176 µM) (Reimão et al. 2010). Further
development of cinnarizine 38will require the synthe-
sis of more active analogues, an approach challenged
by the fact that no target has yet been identiﬁed
(Pinto et al. 2014).
In a separate study we have successfully developed
an enzyme assay to explore the potential of the
Leishmania sphingolipid synthase as a new antileish-
manial drug target (Mina et al. 2010, 2011). This
assay was employed to screen a set of 1040 pharma-
cologically active compounds selected from the
National Institute of Neurological Disorders and
Stroke (NINDS). Many of the most active and
selective hits have reported antihistamine activity.
As these maintained activity in infected cell models
they have considerable potential for repurposing as
target speciﬁc antileishmanials (Brown et al. in
preparation).
Central nervous system (CNS) active drugs
Benzodiazepines are sedatives used to treat anxiety,
insomnia and seizures and various analogues have
been reported to show activity against visceral and
CL (Fig. 10). Compound 39, structurally related to
paullone, demonstrated eﬃcacy against L. donovani
amastigotes with no observed toxicity (Clark et al.
2007). In a separate study, benzodiazepine 40 was
eﬀective against L. mexicana promastigotes with a
better IC50 value than that observed for miltefosine
8 (Navin et al. 2017). However, metabolic studies
using rat hepatocytes and microsomal preparation
showed that the potential of these compounds is
limited by extensive and rapid metabolism.
Therefore, further rounds of medicinal chemistry
optimisation will be required (Thi et al. 2009).
Tricycylic heterocycles are part of numerous
therapeutic agents and therefore important
structures in medicinal chemistry (Marcu et al.
2016). Chlorpromazine 41 is perhaps the best
known of the phenothiazine drugs (tricycylic hetero-
cycles) for treatment of neurological disorders. In
1984 this compound was identiﬁed as having activity
against L. donovani in vitro and in vivo (Pearson et al.
1984) and in a separate study also showed it could
kill L. mexicana, L. aethiopica and L.major promas-
tigotes at a concentration of 7·5 µg mL−1 (El-On
et al. 1986). The same study determined the in
vivo eﬀect for chlorpromazine 41 in a murine
model infected with L. major and L. mexicana and
demonstrated leishmanicidal eﬀect in the spleen
but not in the skin lesion (El-On et al. 1986).
Therefore, like pentamidine, this compound was
shown to be eﬀective against VL but with
only partial eﬀect against the cutaneous form.
Chlorpromazine 41 will probably not be useful in
the treatment of VL due to toxicity concerns but
these results have led to the investigation of structur-
ally similar compounds (Chan et al. 1998;
Mukherjee et al. 2012; Marcu et al. 2016) to
explore the SAR. For example, chlorpromazine ana-
logues with a quaternary nitrogen atom 42 have
demonstrated antileishmanial, antitrypanosomal
and antimalarial activity (Khan et al. 2000; Parveen
et al. 2005). These analogues are trypanothione
reductase inhibitors, which are likely to aﬀect the
redox defense of the parasite and hence increase
the parasites sensitivity to redox-damaged-based
drugs. In addition, the enzyme, trypanothione
reductase, is present in Leishmania andTrypanosoma
but not the mammalian hosts providing the oppor-
tunity to design a selective inhibitor (Khan et al.
2000; Parveen et al. 2005).
HTS against the L. major inositol phosphorylcer-
amide synthase (IPCS) formatted into a cell-based
yeast assay identiﬁed a class of benzazepanes as
potent inhibitors of the enzyme with good activity
against both L. major and intramacrophage L. dono-
vaniwith good levels of selectivity vsHumanTHP-1
cells; on target eﬀects were shown by comparison
with a mutant L. major strain with redundant
sphingolipid synthase activity. However, again
further progression requires improvements to
the pharmacokinetic proﬁle of these compounds
(Norcliﬀe et al., in prep).
The opioid receptor antagonist naloxonazine 43
was identiﬁed in a screen comparing promastigote
and amastigote activity in which it was uniquely
the only compound identiﬁed that showed activity
against the intracellular amastigote and not the pro-
mastigote. Curiously, the structurally related opioid
naloxone (Narcan®) was completely inactive against
both parasitic forms. Since homologs of opioid
receptors have not been identiﬁed in the
Leishmania genome it is possible that opioids are
involved in modulation of host resistance to parasite
infection. In support of this, Loperamide 44, a μ-
Fig. 9. An antihistamine that could be repurposed as an
antileishmanial.
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opioid receptor agonist, was also identiﬁed in this
study as inhibiting parasite growth with greater
activity against the intracellular stage of the parasite
(De Muylder et al. 2011).
Finally, antileishmanial activity was observed
when the broad spectrum antidepressants, ketan-
serin 45 and mianserin 46, were screened against
L. donovani promastigotes and intramacrophage
amastigotes. Amongst other enzymes these com-
pounds are known to target 3-hydroxy-3-methylglu-
taryl coenzyme A reductase (HMGR). This is the
rate-limiting enzyme of the sterol biosynthesis,
which is also the putative pathway targeted by
amphotericin B 5. In support of this proposal both
compounds inhibited recombinant L. donovani
HMGR, although given the diverse reported activ-
ities, other modes of action cannot be discounted
(Dinesh et al. 2014; Singh et al. 2014b).
Other drugs
Similar to ketanserin 45 and mianserin 46 discussed
above, statins target HMGR. Statins are currently
on the market to reduce cardiovascular disease by
lowering the level of low-density lipoprotein choles-
terol (‘bad cholesterol’) in the blood. Studies have
shown that statins also have the potential to be
repurposed as antileishmanials (Kumar et al. 2016;
Parihar et al. 2016). For example, mevastatin 47
also inhibits recombinant L. donovani HMGR
enzyme with an IC50 value of 42·2 ± 3·0 µM. It also
shows correspondingly good activity against both
L. donovani promastigotes and intracellular amasti-
gotes with no toxicity exhibited towards the host
cell line (Dinesh et al. 2015).
Amiodarone 48 and dronedarone 49, (Fig. 11)
used to treat cardiac arrhythmias, have antileishma-
nial activity against L. mexicana promastigotes and
intramacrophage amastigotes, and inhibit oxidos-
qualene cyclase (OSC), another enzyme essential
for ergosterol biosynthesis. However, as with the
antihistamines discussed above, these drugs are
also known to disrupt Ca2+ homeostasis in
Saccharomyces cerevisiae and Trypanosoma cruzi, so
may have multiple modes of action (Serrano-
Martin et al. 2009a). The in vivo activity of amiodar-
one 48 was investigated in a murine model infected
with L. mexicana. amiodarone 48 was given as an
Fig. 10. CNS drugs that could be repurposed as antileishmanials.
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oral therapy at 50 mg kg−1 day−1 and although pre-
venting the development of lesions during the
course of treatment, reoccurrences of the infection
were observed once treatment had ended.
Amiodarone 48 was then tested in combination
with miltefosine 8 at a dose of 50 and 20 mg kg−1
day−1 respectively, and showed permanent control
of lesion size. Hence, using this drug in combination
with currently available antiparasitics could lower
the dosage and reduce the known side eﬀects of
amiodarone (e.g. cardiotoxicity, thyroid dysfunction
and pulmonary ﬁbrosis) (Serrano-Martín et al.
2009b). Alternatively, dronedarone 49 appears to
have great potential to be repurposed as it has
greater antiparasitic activity coupled with lower
mammalian toxicity than amiodarone 48 (Benaim
et al. 2014).
This review has focused on repurposing synthetic
small molecules, though there are studies that have
investigated polymers and natural products. For
instance, a recent study conﬁrmed that polyhexanide
50, a wound antiseptic and disinfectant, has antil-
eishmanial activity with IC50 values of 0·41 µM
against L. major promastigotes, 69-fold more
potent than miltefosine 8, and 4 µM against intracel-
lular L. major amastigotes. Polyhexanide 50 is
thought to kill the parasite by disruption to
membrane structure and selective chromosome
condensation and damage. Interestingly, it was also
discovered that this cationic polymer can be used
as a vehicle to transport cargoes to the macrophage
and thus has the ability to deliver immunomodula-
tory agents (Firdessa et al. 2015).
Whilst the focus of this review has been on repur-
posing human therapeutics, there is the potential for
investigating other groups of bioactive chemicals,
including both agrochemicals and veterinary medi-
cines for human use as treatments for neglected dis-
eases. For example, more than 600 commercial
agrochemicals were screened against parasitic
protozoans and zoxamide 51 was found to be the
most eﬀective against L. donovani promastigotes.
Zoxamide 51 is an oomyceticidal compound used
in fruit and vegetables, and acts through the
inhibition of microtubule formation. Microtubule
inhibitors may be a class of potential antileishma-
nials since tubulin is one of the most abundant
leishmanial proteins (Kapoor et al. 1999).
Zoxamide 51 killed the promastigotes with an IC50
value of 250 nM (Witschel et al. 2012). Although
explored in other contexts (Andrews et al. 2014),
there has been little reported eﬀort to repurpose vet-
erinary medicines for leishmanaisis, possibly due to
the potential human toxicity issues which could
arise and negate the beneﬁts of the repurposing
approach.
Concluding remarks
The repositioning of old drugs for new uses is not a
new concept and is a particularly attractive approach
for neglected tropical diseases. Here the use of
approved drugs is particularly beneﬁcial as clinical
trials have already successfully been conducted and
often their patents have expired leading to shorter,
cheaper discovery pipelines. As discussed in the
various sections above, a wide range of structures
have been explored for antileishmanial activity.
Signiﬁcantly, most of the medicines used to treat
leishmaniasis, both on the market or under devel-
opment in the drug discovery process, were initially
intended for other indications. Furthermore, more
novel approaches show drug repositioning is
extending beyond the scope of human medication
as investigation into the human use of agrochem-
icals and veterinary therapeutics is underway.
However, drug repurposing is limited by the
number of approved drugs and compounds with
established pharmacokinetic data, in addition the
repositioning discovery process tends to mean that
there is less chance of ﬁnding treatments that act
through a new mechanism of action. Overall,
whilst not the sole solution, drug repositioning
represents a valuable, relatively fast and cost-
eﬀective, strategy for developing essential new ther-
apies, particularly for neglected tropical diseases
such as leishmaniasis.
Fig. 11. Other drugs that could be repurposed as
antileishmanials.
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Table 1. List of drugs in this review and their activities
Drug Species In vitro form
EC50
(μM)
Selectivity
index
Animal
study References
10 L. major Promastigotes 0·11 – Y Diaz-Gonzalez et al. (2011)
L. donovani Promastigotes 0·14 N
Axenic amastigotes 0·07
11 L. major Promastigotes 0·12 0·08 N Patel et al. (2014)
Axenic amastigotes 2·37
12 L. donovani Intracellular amastigotes 1·08 7·04 Y Sanderson et al. (2014)
L. mexicana Intracellular amastigotes 2·63 2·89 N
13 L. donovani Intracellular amastigotes 3·73 1·88 Y
L. amazonensis Intracellular amastigotes 6·87 1·02 N
L. mexicana Intracellular amastigotes 4·72 1·48 N
L. major Intracellular amastigotes 3·77 1·86 N
14 L. donovani Intracellular amastigotes 2·49 2·41 Y
15 L. amazonensis – – – Y Wetzel et al. (2012)
16 L. donovani Axenic amastigotes 0·47 10 N Wang et al. (2015)
17 L. amazonensis Promastigotes 13·51 – Y Trinconi et al. (2016)
Intracellular amastigotes 4·25
18 L. amazonensis Promastigotes 30·2 1·77 Y Reimao et al. (2014)
Intracellular amastigotes 16·2
19 L. major Intracellular amastigotes >105 – Y Berman and Gallalee (1987)
20 L. major – – – Y Zakai and Zimmo (2000)
21 L. major Promastigotes 136 1·82 Y Shokri et al. (2017)
Intracellular amastigotes 24
22 L. amazonensis Promastigotes 0·44 187·5 Y de Macedo-Silva et al. (2013),
Zakai and Zimmo (2000)Intracellular amastigotes 0·08
23 L. amazonensis Promastigotes 2·74 12·2 Y de Macedo-Silva et al. (2013)
Intracellular amastigotes 1·63
24 L. infantum Promastigotes 2–8 3·6 N Mesquita et al. (2014)
Intracellular amastigotes 11
25 L. major Intracellular amastigotes 0·015 >407 N Khraiwesh et al. (2016)
26 0·061 >100
27 0·091 14·2
28 0·13 >45·4
29 L. infantum Promastigotes 139 3·09 N Mesquita et al. (2013)
Intracellular amastigotes 22
L. donovani – – – Y Zhang et al. (2010)
L. amazonensis Promastigote 7·2 115 N Nava-Zuazo et al. (2014)
30 L. donovani Promastigotes 5·6 >17·9 Y Wyllie et al. (2012)
Axenic amastigotes 2·8
Intracellular amastigotes Inactive –
31 L. amazonensis – – – Y Rodrigues et al. (2006)
32 L. amazonensis – – – Y Rodrigues et al. (2006)
33 L. donovani Promastigotes 0·9 >10 Y Patterson et al. (2013)
Intracellular amastigotes 4·92
34 L. donovani Promastigotes 0·16 >54 Y Patterson et al. (2013)
Intracellular amastigotes 0·93
35 L. donovani Promastigotes 0·016 >3125 Y Patterson et al. (2016)
Axenic amastigotes 0·005 >10 000
Intracellular amastigotes 0·087 >575
36 L. donovani Intracellular amastigotes Inactive – Y Smith et al. (2000)
37 L. donovani Promastigotes Inactive – N Buates and Matlashewski (1999)
Axenic amastigotes Inactive –
Intracellular amastigotes Active –
L. major Intracellular amastigotes 21–42 – Y El-On et al. (2007)
38 L. infantum Promastigotes 34 4·14 Y Pinto et al. (2014)
Intracellular amastigotes 21
39 L. donovani Intracellular amastigotes Active – N Clark et al. (2007)
40 L. mexicana Promastigotes 1·24 – N Navin et al. (2017)
41 L. donovani Intracellular amastigotes 4·90 – Y Chan et al. (1998)
42 L. donovani Intracellular amastigotes 8·60 0·55 N Parveen et al. (2005)
43 L. donovani Promastigotes >50 9·68 N De Muylder et al. (2011)
Axenic amastigotes >50
Intracellular amastigotes 3·45
44 L. donovani Promastigotes 17·30 3·02 N De Muylder et al. (2011)
Axenic amastigotes >50
Intracellular amastigotes 5·40
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